Synthesis, identification and molecular docking of a new azo dye ligand with a Pt(IV) complex and evaluation of its impact on the expression of BCL-2, an anti-apoptotic marker in cancer cells
A new metal complex of Pt(IV) with a new ligand 2-[2'-(6-methoxybenzothiazolyl) azo]-3,4-dimethylbenzoic acid (6-MBTAMB), derived from 2-amino-6-methoxy benzothiazole, was prepared. This metal complex was described by spectroscopic techniques: UV-Vis, FT-IR, 1H NMR, mass spectrometry, FE-SEM, XRD, and elemental analysis (C.H.N.S). The results certain that the azo dye ligand is a tridentate and coordinates to the metal ion by the nitrogen atom of the azomethine group of the heterocyclic benzothiazole ring, the nitrogen atom of the azo group which is the furthest of the benzothiazole molecule and the oxygen atom of the hydroxyl group. Molecular docking was used to define how effective these compounds are against cancer. (6-MBTAMB) and Pt(IV) complex were studied for toxicity in breast cancer (MCF-7(, the antioxidant and anticancer activities were performed by evaluating (MCF-7) proliferation, intracellular contents of catalase and malondialdehyde (MDA) levels and were compared to non-treated (MCF-7) cell line. The BCl-2 expression levels were also investigated. Moreover, one hundred twenty participants were registered in this paper, sixty women with breast cancer and sixty as controls. The change in the oxidant-antioxidant system was also determined by measuring (MAD) and catalase levels in addition to evaluating the change in the gene expression levels of BCL-2. Interestingly, the levels of BCL-2 were reversed in (MCF-7) cells treated with the complex.